This new designation is very promising for muscular dystrophy
For FSHD patients and their family and friends, this new designation is very promising. Not only will research continue, but patients can be hopeful for new treatment options.
FSHD may not be a fatal disease, but it’s certainly a tough one. It has a serious and often times very negative impact on a person’s life. It’s restrictive and causes pain and is very hard to live with. If companies like Acceleron Pharma continue to strive to find options for these rare diseases like FSHD, patients will have a better quality of life.